RE:RE:RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 monthsIn response to inthno - although AMBRX completed a Phase 3 in China - there is no transferability of results to either the United States or the European Union (EU). What inthno wants everyone to believe is that AMBRX was further along than it really is. One doesn't need to spend time in asking the question of why he seeks to misinform.
The simple fact is that AMBRX is still a Phase 1/2 clinical development company in the regulated markets of the US, the EU, and the ROW, ex. China.